Senolytics in early human trials: what dasatinib plus quercetin and fisetin actually showed, and the senescence-marker problem

Key takeaways

• Senolytics are drugs that selectively kill senescent cells. The lead program is the dasatinib + quercetin (D+Q) combination identified by Zhu et al. 2015 at Mayo Clinic.
• The Hickson 2019 IPF pilot (14 subjects, open-label) showed modest physical-function improvement; the Justice 2019 diabetic kidney pilot (9 subjects) demonstrated reduced senescent-cell burden in adipose biopsy.
• Dasatinib (Sprycel) is FDA-approved for chronic myeloid leukemia at continuous 50-180 mg/day with substantial labeled adverse-event burden (pleural effusion, cardiac dysfunction, myelosuppression).
• Senolytic dosing is intermittent (~100 mg dasatinib for 2-3 days, repeated every 2-4 weeks); long-term safety of repeated pulses is not characterized in published trials.
• Unity Biotechnology UBX0101 (intra-articular MDM2-p53 senolytic) failed phase 2 for knee osteoarthritis in 2020; the failure does not invalidate the senolytic hypothesis but shows single-mechanism trials can fail.

What senescent cells are, and why they matter

Cellular senescence is a state of stable cell-cycle arrest accompanied by a distinctive secretory program known as the senescence-associated secretory phenotype (SASP). SASP components include pro-inflammatory cytokines, chemokines, growth factors, and matrix-remodeling enzymes. In animal models, senescent cells accumulate with age and contribute to chronic low-grade inflammation, tissue dysfunction, and several age-related disease phenotypes .

The senolytic hypothesis is that pharmacologically clearing senescent cells will reduce their pathological contribution to aging tissues. Foundational mouse work by Baker and colleagues (2011, 2016) used a genetic model (INK-ATTAC) to selectively kill p16+ senescent cells and reported improvements in healthspan and a modest extension of median lifespan. The pharmacological program then asked whether small molecules could achieve a similar outcome .

The D+Q discovery (Zhu et al. 2015)

Zhu and colleagues (2015) at Mayo Clinic and Scripps screened compounds for senolytic activity in cultured senescent cells and reported that dasatinib (a tyrosine kinase inhibitor approved for chronic myeloid leukemia) and quercetin (a flavonoid) each killed senescent cells in different lineages, with the combination (D+Q) clearing senescent cells more broadly than either alone .

Subsequent mouse work using D+Q reported reduced senescent-cell burden in tissues, improved physical function in aged mice, attenuated atherosclerosis progression, and other age-related phenotype improvements. These data motivated the first human trials.

The Hickson IPF pilot (2019)

Hickson and colleagues (2019) ran an open-label single-arm pilot of D+Q in 14 adults with idiopathic pulmonary fibrosis (IPF), an age-associated disease where senescent fibroblasts and alveolar epithelial cells are implicated. Subjects received intermittent D+Q (dasatinib 100 mg + quercetin 1250 mg daily for 3 days, repeated for 3 weeks). Physical function endpoints (6-minute walk distance, gait speed, chair-stand) improved modestly over the short follow-up .

Caveats: 14 subjects, no placebo arm, short duration, surrogate endpoints. The result is consistent with the preclinical hypothesis but is hypothesis-generating rather than confirmatory. The trial was not designed to test mortality or hard pulmonary outcomes.

The Justice diabetic kidney pilot (2019)

Justice and colleagues (2019) ran a separate open-label D+Q pilot in 9 adults with diabetic kidney disease, using a single 3-day course of D+Q followed by adipose biopsy 11 days later. The biopsy demonstrated reduced senescent-cell burden (p16, p21, SASP markers) in subcutaneous adipose tissue and reduced circulating SASP biomarkers .

This is the closest published evidence that a single D+Q course actually clears senescent cells in human tissue. The trial was small, open-label, and biomarker-focused; it did not test clinical outcomes.

Ongoing D+Q clinical program

The Translational Geroscience Network and Mayo Clinic have multiple ongoing or recently completed D+Q trials registered on ClinicalTrials.gov, covering Alzheimer's disease, age-related skeletal muscle dysfunction, frailty, post-COVID syndrome, and bone marrow transplant survivorship . Most are small to moderate in size and use surrogate endpoints (senescence biomarkers, physical function, cognitive measures) rather than mortality.

As of 2026, no large randomized D+Q trial with hard outcome endpoints in a healthy aging population has been published. The clinical program is real and progressing but remains pre-confirmatory.

Dasatinib (Sprycel): the label and intermittent-dose safety

Dasatinib is FDA-approved as Sprycel for chronic myeloid leukemia and Philadelphia-chromosome-positive acute lymphoblastic leukemia, dosed continuously at 50-180 mg/day. The labeled adverse-event profile at continuous dosing is substantial :

• Pleural effusion (~28 percent rate at 100 mg daily continuous dosing).
• Pulmonary arterial hypertension.
• Cardiac dysfunction (QT prolongation, congestive heart failure, ventricular dysfunction).
• Severe hemorrhage (CNS, GI).
• Myelosuppression (neutropenia, thrombocytopenia, anemia).
• Fluid retention syndromes beyond pleural effusion (pericardial effusion, ascites, generalized edema).

Senolytic dosing is intermittent (typically 100 mg dasatinib for 2-3 consecutive days, repeated every 2-4 weeks), and the cumulative exposure is dramatically lower than the continuous oncology dose. Empirically, the published senolytic trials have not reported the full continuous-dosing adverse-event burden, but the intermittent-dose long-term safety profile (months to years of repeated pulses) is not yet characterized in published trials. Quercetin at the senolytic dose (1000-1500 mg) is an unusually high oral flavonoid load; tolerability appears acceptable in published trials but long-term effects on iron absorption, kidney function, and CYP-substrate drug interactions are less well-studied than the active drug component.

Fisetin: the alternate flavonoid senolytic

Fisetin, another flavonoid, was identified as a senolytic in mouse screens by the Niedernhofer / Robbins group and is now in human trials in older adults. Fisetin trials registered on ClinicalTrials.gov include studies in adults with frailty, in adults with diabetic kidney disease, and in osteoarthritis pain populations . Reported outcomes from completed trials are limited as of 2026; the program is at the same surrogate-endpoint stage as D+Q.

Fisetin is sold widely as a dietary supplement at doses well below the senolytic dose used in trials. Whether supplement-dose fisetin produces meaningful senolytic activity in humans is not established. Trial-dose fisetin is gram-scale (1000-1500 mg), which is also a flavonoid load above typical dietary intake.

The UBX0101 osteoarthritis program failure

Unity Biotechnology developed UBX0101, an MDM2-p53 senolytic, for intra-articular injection in knee osteoarthritis. Phase 1 results were promising. The phase 2 trial failed to meet its primary pain endpoint at 12 weeks; Unity discontinued the program in 2020. The failure does not invalidate the senolytic hypothesis (different molecule, different tissue, different endpoint), but it is a useful counterpoint to the assumption that a single senolytic course will reliably move clinical endpoints in any indication .

The senescence-quantification problem

There is no validated single-cell or single-blood-test biomarker for senescent-cell burden in humans. p16INK4a expression in T cells, circulating SASP cytokines, blood TBM-1 and growth differentiation factor 15 (GDF15), and tissue biopsy with multiple p16/p21/SASP staining are all imperfect proxies. Any single marker can move in response to non-senescent stimuli (acute inflammation, infection, exercise), and the markers do not always correlate with each other.

This is the central methodological challenge for the field. Without a clean biomarker, the trials must rely on functional endpoints (physical performance, disease-specific outcomes) which are slower to move and noisier than a clean cellular marker would be. The Justice 2019 biopsy approach is the most direct demonstration of senescent-cell clearance in human tissue but does not scale to large outcome trials.

What the trials do not answer

• Whether intermittent senolytic courses reduce mortality or hard age-related disease endpoints over multi-year follow-up.
• What the optimal interval between senolytic courses is.
• Whether D+Q, fisetin, or future senolytics differ meaningfully in tissue-specific clearance patterns.
• Whether the lack of a clean biomarker is hiding heterogeneity (responders vs non-responders).
• How the intermittent-dose long-term safety profile of dasatinib compares to continuous oncology dosing across years of repeat exposure.

Editorial summary

Senolytics in 2026 are at the same stage as rapamycin was in the early 2010s: strong preclinical signal, small open-label or single-arm pilots in humans, and a clear demonstration of tissue-level mechanism (Justice 2019). The field needs larger placebo-controlled trials with hard endpoints. The dasatinib safety profile at continuous dosing is meaningful and the intermittent dosing rationale is plausible but not yet fully validated.